The race to treat COVID-19 | All eyes are on this company right now

Shares :



Since March 2020, we have been living through one of the worst global health crises in modern history. Since that time there has been a race against time to find a cure or a vaccine. Millions are invested by governments and the biggest companies in biotech.

Since the start of the pandemic, investors have been looking for companies that can get them rich with the solution to COVID-19.

A small company among the big ones among the big ones

A small penny stock is now in the race against huge pharmaceuticals with an application to the U.S. Food and Drug Administration (“U.S. FDA”) for a Phase 3 confirmatory study for Bucillamine as a potential treatment in COVID-19.

On 23th April, Revive Therapeutics announces US FDA Recommendation to Proceed Directly Into A Phase 3 Confirmatory Clinical Trial to evaluate Bucillamine for the treatment of patients with mild-moderate COVID-19 due to the SARS-CoV-2 infection.

Then on June 30, the company announced that it has submitted its Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“U.S. FDA”) for a Phase 3 confirmatory study for Bucillamine as a potential treatment in COVID-19.

Finally U.S. FDA approval phase 3

Updated July 31, Revive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19

Chief Executive Officer Michael Frank, is very excited about upcoming developments for the company and investors.

“The FDA approval of the Phase 3 study to evaluate Bucillamine in the treatment of patients with mild-moderate COVID-19 is a tremendous milestone for Revive and I am very proud of the dedication of our team and partners to bring forward a potential new treatment option for patients with a confirmed diagnosis of COVID-19 globally,”

“We thank the FDA for recognizing the importance of this Phase 3 study and we are now focused on executing on our plans for initiating the clinical trial in an expeditious manner.”

Huge potential

With a market value of less than $50M currently, Revive Therapeutics can prove to be a gold mine for investors if compared with the average value of companies in phase 3 with the FDA.

Source : baybridgebio

Revive Therapeutics market value of less than $50M currently

Revive Therapeutics is therefore now in the big leagues with this announcement and we can expect many announcements and development which should propel the company to new heights.

Revive Therapeutics surged 68% on news to close at $0.39


Revive Therapeutics trades on the CSE with the symbol RVV

Sign up for MORE news updates !

This article is written and published by The Cannabis Stock

Disclaimer : The Cannabis Stock wants to promote the cannabis market with the best articles and news on the market. The Cannabis Stock does not recommend selling or buying any of the company mentioned and is not responsible for any losses that may result. The Cannabis Stock are engaged in the business of marketing and advertising companies

The Cannabis Stock and its employees may from time to time own shares of the companies named in the articles. All the facts reported by the cannabis stock are information that comes directly from the companies, from their website or on Sedar and are only published as information.

Disclosure : Revive Therapeutics Ltd is a paid clients of The Cannabis Stock.

Click on a star to rate this article !

Average rating 5 / 5. Vote count: 7

No votes so far! Be the first to rate this post.

Shares :